查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917886

聚合物生物材料市场－2026-2031年预测

Polymeric Biomaterials Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计聚合物生物材料市场将从 2025 年的 561.86 亿美元成长到 2031 年的 1,315.89 亿美元，复合年增长率为 15.24%。

聚合物生物材料市场是一个基础性强且发展迅速的领域，它位于材料科学、工程和医学的交叉领域。这些材料被定义为合成或天然聚合物，经过工程设计可与生物系统相互作用，并在体内发挥特定功能，涵盖结构支撑、药物传输、组织再生和器械整合等。它们独特的性能，例如可调控的降解速率、机械强度、生物相容性和表面功能性，使其能够应用于包括整形外科、循环系统医学、神经病学和牙科在内的众多医学领域。市场成长的驱动力来自材料科学的进步、人口结构和疾病趋势带来的临床需求成长，以及向个人化和再生医学解决方案的模式转移。

推动聚合物生物材料成长要素源自于临床对先进治疗和再生医学应用日益增长的需求。聚合物生物材料在再生医学领域至关重要，可作为组织工程的支架、可控药物和基因传递的载体以及微创细胞移植的注射基质。透过设计具有精确降解特性和生物活性讯号的聚合物，可以建构支持组织修復和再生的微环境。这种能力对于满足复杂创伤治疗、器官修復和慢性退化性疾病治疗等领域的未满足需求至关重要，使聚合物生物材料成为下一代治疗方法的关键平台。

同时，慢性及老龄化肌肉骨骼疾病（MSDs）在全球范围内的日益普遍是推动市场发展的关键因素。骨关节炎、脊髓退化以及创伤或疾病导致的骨缺损等疾病，使得整形外科植入和骨移植替代材料的需求显着增加。包括聚乳酸-羟基乙酸共聚物（PLGA）和聚己内酯（PCL）等可生物降解聚合物在内的聚合物生物材料，被广泛应用于缝合线、固定装置和可吸收支架中，这些材料在提供临时机械支撑的同时，还能促进自然癒合。向生物活性可吸收植入的转变，避免了二次取出手术的需要，是推动整形外科领域创新和应用的关键趋势。

人口结构变化，尤其是全球人口老化，进一步推动了市场的持续扩张。老年人患有需要医疗干预的疾病（例如心血管疾病、关节退化性疾病和牙科疾病）的比例更高。这一人口趋势正在推动对各种植入器材的需求，从支架和心臟瓣膜到关节重建和牙科修补，其中许多器械的功能和生物相容性都依赖聚合物组件。长期植入对耐用、无血栓形成性和抗感染材料的需求，持续推动先进聚合物化学领域的研究和开发。

技术创新是推动市场发展和创造机会的持续动力。目前的研究重点在于开发具有增强功能的「智慧型」聚合物系统，例如刺激响应型药物释放、固有抗菌性能以及调节免疫反应的能力。生物可吸收聚合物和共聚物的研发是产业相关人员的关键策略方向。这些材料旨在为患者提供指定时间内所需的机械支撑，然后降解为可安全代谢的产物，从而消除长期异物风险和二次手术取出的需要。共聚物设计、共混和表面改质方面的创新旨在更好地控制降解速率、机械性能以及与宿主组织的整合。

从区域来看，北美凭藉主导系统、充足的公共和私人生物医学创新资金（例如透过国家科学基金会等机构）以及成熟的医疗设备产业（拥有完善的监管和商业化体系），保持着领先地位。大型製药和医疗技术公司的存在，促进了材料科学突破快速转化为临床产品。同时，亚太地区被公认为高成长市场，其成长动力来自不断增长的医疗费用支出、不断扩大的医疗基础设施、日益​​提升的国内製造能力，以及区域和全球企业为加强其在新兴经济体的业务而采取的战略倡议。

在竞争格局中，特种化学品製造商、生医材料专家和大型医疗设备製造商是主要参与者。关键策略活动包括对新型聚合物合成和配方技术进行研发投资、与学术和临床研究机构建立策略联盟，以及专注于获得新材料适应症的监管核准。各公司也正在投资扩大临床级材料的生产规模，以满足大规模治疗应用的需求。

总之，聚合物生物材料市场对现代医学的发展至关重要，为创新医疗设备和再生医学提供了必要的材料基础。其成长轨迹与个人化医疗、微创治疗以及应对全球老化人口复杂慢性疾病等前沿领域密切相关。未来市场参与企业的成功将取决于其设计具有日益复杂生物相互作用的聚合物的能力，透过严格的临床检验证明其安全性和有效性，以及应对力植入材料相关复杂监管环境的能力。聚合物科学的持续发展有望开创新的治疗模式，确保该市场在塑造未来医疗保健格局中发挥核心作用。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势，以及它们将如何塑造未来的市场发展。
  • 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 聚合物生物材料市场（依来源划分）

  • 介绍
  • 自然的
  • 合成

6. 按产品类型分類的聚合物生物材料市场

  • 介绍
  • 聚乳酸（PLA）
  • 聚乙醇酸（PGA）
  • 聚氨酯（PU）
  • 聚丙烯
  • 其他的

7. 按应用分類的聚合物生物材料市场

  • 介绍
  • 神经病学
  • 心臟病学
  • 整形外科
  • 眼科
  • 创伤护理
  • 其他的

8. 按最终用户分類的聚合物生物材料市场

  • 介绍
  • 医院
  • 专科诊所
  • 其他的

9. 各地区聚合物生物材料市场

  • 介绍
  • 北美洲
    • 按来源
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 我们
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按来源
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按来源
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 德国
      • 法国
      • 英国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 按来源
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按来源
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 印尼
      • 泰国
      • 台湾
      • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十一章 公司简介

  • Corbion
  • Evonik Industries
  • Mitsubishi Chemical Group
  • DSM-Firmenich
  • Covestro
  • Bezwada Biomedical, LLC
  • Stryker Corporation
  • Victrex Plc
  • Reva Medical, LLC
  • NatureWorks LLC（Cargill Incorporated）

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615901

Polymeric Biomaterials Market, with a 15.24% CAGR, is expected to grow to USD 131.589 billion in 2031 from USD 56.186 billion in 2025.

The polymeric biomaterials market constitutes a foundational and rapidly evolving segment at the intersection of materials science, engineering, and medicine. Defined as synthetic or natural polymers designed to interact with biological systems, these materials are engineered to perform specific functions within the body, ranging from structural support and drug delivery to tissue regeneration and device integration. Their unique properties-including tunable degradation rates, mechanical strength, biocompatibility, and surface functionality-enable their application across a broad spectrum of medical fields, including orthopedics, cardiovascular medicine, neurology, and dentistry. Market growth is propelled by the convergence of advancing material science, rising clinical demand driven by demographic and disease trends, and a paradigm shift towards personalized and regenerative medical solutions.

A primary and powerful growth driver is the escalating clinical demand for advanced therapeutic and regenerative applications. Polymeric biomaterials are indispensable in the field of regenerative medicine, serving as scaffolds for tissue engineering, carriers for controlled drug and gene delivery, and as injectable matrices for minimally invasive cell transplantation. The ability to engineer polymers with precise degradation profiles and bioactive cues allows for the creation of supportive microenvironments that guide tissue repair and regeneration. This capability is critical for addressing unmet needs in complex wound healing, organ repair, and the treatment of chronic degenerative diseases, positioning polymeric biomaterials as enablers of next-generation therapies.

Parallel to this, the increasing global prevalence of chronic and age-related musculoskeletal disorders (MSDs) is a significant market catalyst. Conditions such as osteoarthritis, spinal degeneration, and bone defects resulting from trauma or disease generate substantial demand for orthopedic implants and bone graft substitutes. Polymeric biomaterials, including biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL), are extensively used in sutures, fixation devices, and resorbable scaffolds that provide temporary mechanical support while promoting natural bone healing. The shift towards bioactive and resorbable implants that eliminate the need for secondary removal surgeries is a key trend, driving innovation and adoption in the orthopedic segment.

Demographic shifts, specifically the aging of the global population, further underpin sustained market expansion. Older adults exhibit a higher incidence of conditions requiring medical intervention, such as cardiovascular disease, joint degeneration, and dental pathologies. This demographic trend amplifies the demand for a wide array of implantable devices-from stents and heart valves to joint replacements and dental prosthetics-many of which rely on polymeric components for their functionality and biocompatibility. The need for durable, non-thrombogenic, and infection-resistant materials in long-term implants continues to drive research and development in advanced polymer chemistries.

Technological innovation is a constant driver of market evolution and opportunity. Ongoing research focuses on developing "smart" polymeric systems with enhanced functionalities, such as stimuli-responsive drug release, inherent antimicrobial properties, and the ability to modulate immune responses. A significant strategic focus for industry participants is the advancement of bioresorbable polymers and copolymers. These materials are engineered to provide necessary mechanical support for a defined period before safely degrading into metabolizable byproducts, thereby eliminating long-term foreign body risks and the need for secondary surgical removal. Innovations in copolymer design, blending, and surface modification are aimed at achieving superior control over degradation kinetics, mechanical properties, and integration with host tissue.

Geographically, North America maintains a leading position, supported by a robust ecosystem of academic research, substantial public and private funding for biomedical innovation (through agencies like the National Science Foundation), and a mature medical device industry with strong regulatory and commercialization pathways. The presence of major pharmaceutical and medical technology companies fosters rapid translation of material science breakthroughs into clinical products. Concurrently, the Asia-Pacific region is identified as a high-growth market, driven by increasing healthcare expenditure, expanding medical infrastructure, rising domestic manufacturing capabilities, and strategic initiatives by both regional and global companies to establish a stronger presence in these emerging economies.

The competitive landscape features specialty chemical companies, dedicated biomaterial firms, and large medical device corporations. Key strategic activities include significant investment in R&D for novel polymer synthesis and formulation, strategic partnerships with academic and clinical research centers, and a focus on securing regulatory approvals for new material indications. Companies are also investing in scaling up manufacturing processes for clinical-grade materials to meet the demands of large-scale therapeutic applications.

In conclusion, the polymeric biomaterials market is integral to the advancement of modern medicine, providing the essential material building blocks for innovative medical devices and regenerative therapies. Its growth trajectory is firmly linked to the frontiers of personalized medicine, minimally invasive interventions, and the treatment of an aging global population with complex chronic conditions. Future success for market participants will hinge on the ability to engineer polymers with increasingly sophisticated biological interactions, demonstrate safety and efficacy through rigorous clinical validation, and navigate the complex regulatory landscapes governing implantable materials. The ongoing evolution of polymer science promises to unlock new therapeutic paradigms, ensuring the market's central role in shaping the future of healthcare.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Polymeric Biomaterials Market Segmentation

  • By Source
  • Natural
  • Synthetic
  • By Product Type
  • Polylactic Acid (PLA)
  • Polyglycolic Acid (PGA)
  • Polyurethane (PU)
  • Polypropylene
  • Others
  • By Application
  • Neurology
  • Cardiology
  • Orthopedic
  • Ophthalmology
  • Wound Care
  • Others
  • By End-User
  • Hospitals
  • Specialty Clinics
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. POLYMERIC BIOMATERIALS MARKET BY SOURCE

  • 5.1. Introduction
  • 5.2. Natural
  • 5.3. Synthetic

6. POLYMERIC BIOMATERIALS MARKET BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. Polylactic Acid (PLA)
  • 6.3. Polyglycolic Acid (PGA)
  • 6.4. Polyurethane (PU)
  • 6.5. Polypropylene
  • 6.6. Others

7. POLYMERIC BIOMATERIALS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Neurology
  • 7.3. Cardiology
  • 7.4. Orthopedic
  • 7.5. Ophthalmology
  • 7.6. Wound Care
  • 7.7. Others

8. POLYMERIC BIOMATERIALS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Specialty Clinics
  • 8.4. Others

9. POLYMERIC BIOMATERIALS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Source
    • 9.2.2. By Product Type
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Source
    • 9.3.2. By Product Type
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Source
    • 9.4.2. By Product Type
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. France
      • 9.4.5.3. United Kingdom
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Source
    • 9.5.2. By Product Type
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Source
    • 9.6.2. By Product Type
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. India
      • 9.6.5.3. Japan
      • 9.6.5.4. South Korea
      • 9.6.5.5. Indonesia
      • 9.6.5.6. Thailand
      • 9.6.5.7. Taiwan
      • 9.6.5.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Corbion
  • 11.2. Evonik Industries
  • 11.3. Mitsubishi Chemical Group
  • 11.4. DSM- Firmenich
  • 11.5. Covestro
  • 11.6. Bezwada Biomedical, LLC
  • 11.7. Stryker Corporation
  • 11.8. Victrex Plc
  • 11.9. Reva Medical, LLC
  • 11.10. NatureWorks LLC (Cargill Incorporated)

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations